Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Down 1.2% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX) is a biotechnology company known for its focus on developing therapies for cystic fibrosis and other serious diseases. The overall market sentiment has been bearish today.

Why is Vertex Pharmaceuticals Incorporated going down?

VRTX stock is down 1.2% on Sep 30, 2025 14:50

• The bearish movement in VRTX could be due to profit-taking by investors after a period of significant gains.
• The bullish analyst upgrades for other companies may have diverted attention and capital away from VRTX, leading to a decline in its stock price.
• Investors might be rotating out of biotech stocks like VRTX and into other sectors, following the shifting recommendations from top Wall Street analysts.
• Overall, the bearish movement in VRTX today could be a combination of sector rotation, profit-taking, and the influence of bullish sentiment on other stocks in the market.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Adient ( NYSE:ADNT ) , Chewy ( NYSE:CHWY )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-stock-ratings/upgrades/25/09/47861541/this-chewy-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday

Trending Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 127.8% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 5.3% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 15.4% Today

Halliburton Company ($HAL) Stock Forecast: Up 11.3% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 8.7% Today

RTX Corporation ($RTX) Stock Forecast: Up 7.7% Today

Philip Morris International Inc ($PM) Stock Forecast: Down 7.0% Today

Solana ($SOL) Crypto Forecast: Up 5.3% Today

PACCAR Inc. ($PCAR) Stock Forecast: Up 0.2% Today

Ford Motor Company ($F) Stock Forecast: Up 5.0% Today

Vertex Pharmaceuticals Incorporated Price History

11.03.2025 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals (VRTX) stock had a strong bullish movement today, possibly driven by the news of securing approval for the expanded use of its CF drug Kaftrio in Europe.
• The expanded use of Kaftrio to treat a larger population in the EU with rare mutations of cystic fibrosis could have positively impacted investor sentiment and contributed to the stock's upward momentum.
• The positive news of regulatory approval for Vertex's drug in a new market could have instilled confidence in investors regarding the company's growth potential and future revenue streams, leading to the bullish movement in the stock price today.

31.00.2025 - VRTX Stock was up 5.6%

• VRTX saw a decrease of -0.72% amidst the overall bullish market trend.
• Investor sentiment towards VRTX might have been impacted by a recent downgrade from an Everest Group analyst.
• The altered outlook could have prompted caution among investors, resulting in a slight retreat in the stock's value.
• When trading VRTX, it is important for traders to weigh both analyst evaluations and market patterns.

13.00.2025 - VRTX Stock was down 1.9%

• Vertex Pharmaceuticals (VRTX) encountered a bearish trend attributed to a Death Cross, signaling a downturn as the stock dropped beneath crucial moving averages.
• Clinical trial setbacks and technical sell signals exerted downward pressure on VRTX, resulting in a 15% decrease over the last half-year.
• Despite recent negativity, Vertex Pharmaceuticals has historically surpassed the market, boasting a 20.1% average annual return over 20 years.
• Investor comparisons of VRTX against peers in the Medical Biomedical and Genetics sector, such as Incyte (INCY), potentially influenced the bearish outlook on Vertex Pharmaceuticals today.

16.08.2025 - VRTX Stock was down 1.8%

• VRTX stock faced a notable decline, closing at $388.55, reflecting a -2% drop from the prior day.
• Although Vertex Pharmaceuticals has a historically strong performance, the recent decline in the market might be linked to profit-taking among investors.
• The broader market surge could have prompted some traders to redistribute their investments, resulting in a brief downturn in VRTX stock.
• Investors are advised to stay vigilant about forthcoming healthcare sector updates that could influence Vertex Pharmaceuticals' stock behavior.

05.07.2025 - VRTX Stock was down 18.4%

• Vertex Pharmaceuticals (VRTX) experienced a strong bearish movement today.
• The bearish trend could be attributed to analysts cutting their forecasts for the company after the Q2 results, despite reporting better-than-expected earnings. This adjustment may have led to a loss of investor confidence.
• Additionally, the disappointing results of the VX-993 trial might have contributed to the negative sentiment surrounding the stock, as investors may have been expecting more positive outcomes.
• Overall, the combination of lowered forecasts and unsatisfactory trial results likely led to the bearish movement in Vertex Pharmaceuticals' stock today.

31.00.2025 - VRTX Stock was up 6.9%

• VRTX stock experienced a strong bullish movement.
• Vertex Pharmaceuticals secured FDA approval for a non-opioid pain treatment and reached a reimbursement agreement with NHS England for its gene therapy, driving positive sentiment.
• The market reacted positively to these advancements in pain management and expanded access to treatments for sickle cell disease, propelling VRTX stock higher.

05.07.2025 - VRTX Stock was down 13.7%

• There was a notable downward movement in the stock today.
• Recent reports on Q2 earnings and VX-993 trial outcomes fell short of projections, contributing to a decrease in the stock's value.
• Despite a generally positive market environment, with Dow futures seeing a slight increase of about 0.1%, Vertex Pharmaceuticals experienced a substantial decline following disappointing trial results.
• Analysts have been closely monitoring the company's stock performance, noting its history of outperforming the market but encountering challenges in the current quarter.

30.08.2025 - VRTX Stock was down 1.2%

• The bearish movement in VRTX could be due to profit-taking by investors after a period of significant gains.
• The bullish analyst upgrades for other companies may have diverted attention and capital away from VRTX, leading to a decline in its stock price.
• Investors might be rotating out of biotech stocks like VRTX and into other sectors, following the shifting recommendations from top Wall Street analysts.
• Overall, the bearish movement in VRTX today could be a combination of sector rotation, profit-taking, and the influence of bullish sentiment on other stocks in the market.

14.04.2025 - VRTX Stock was down 5.3%

• Despite Vertex Pharmaceuticals' strong performance over the past 15 years, the stock faced a bearish movement today.
• Speculation that Vertex Pharmaceuticals will bounce suggests that there may be underlying factors contributing to the temporary decline.
• The market may be reacting to short-term fluctuations or profit-taking by investors, leading to the bearish movement in VRTX today.
• Investors should monitor the situation closely to determine if this is a temporary dip or the beginning of a more sustained trend.

08.06.2025 - VRTX Stock was up 2.3%

• Vertex Pharmaceuticals (VRTX) saw a strong bullish movement, closing at $452.16 with a +1.56% change.
• The bullish movement in VRTX could be attributed to positive developments in its pipeline or potential regulatory approvals.
• Despite the overall market dip, investors showed confidence in Vertex Pharmaceuticals, possibly due to promising clinical trial results or optimistic revenue forecasts.
• The resilience of VRTX in a slightly bearish market indicates strong investor sentiment and belief in the company's growth prospects.

06.04.2025 - VRTX Stock was down 10.9%

• Experienced a strong bearish movement today.
• Fell after missing analyst estimates on both earnings and revenue for the first quarter.
• Despite raising the low end of its full-year 2025 revenue guidance, the market reacted negatively to the missed expectations.
• Analyst downgrades and concerns about the company's recent performance may have contributed to the bearish trend in the stock price.

11.02.2025 - VRTX Stock was down 2.7%

• The bearish movement in VRTX stock today might be due to the pricing placement of their newly approved pain treatment, Journavx, on UnitedHealth's Optum Rx formularies.
• Concerns may arise over the $15.50 cost per 50 mg tablet of Journavx, which surpasses that of opioids, potentially affecting its market acceptance and profitability.
• Despite Vertex's robust Q4 sales figures, market response to Journavx's pricing strategy could have overshadowed positive financial outcomes, contributing to the downtrend in the stock price today.